Skip to main content

Table 1 Basic characteristics of the included studies

From: Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Study Year Cancer type Country Study type Study period No. of cases Male patients, n (%) Age, years Survival type Treatment Stage ALI cutoff value Cutoff selection method
Jafri et al. [25] 2013 NSCLC USA R 2000–2011 173 116 (67%) 57 (34–88) OS, PFS No surgery Metastatic 18.4 ROC curve analysis
He et al. [29] 2015 SCLC China R 2006–2011 365 310 (84.9%) 59 (22–82) OS No surgery Mixed 19.50 Cutoff Finder
Kim et al. [30] 2016 SCLC Korea R 2010–2015 186 156(83.9%) 68.9 ± 9.4 OS No surgery Mixed 31.1 Cutoff value
Park et al. [31] 2017 Diffuse large B cell lymphoma Korea R 2006–2014 212 142 (67%) 59 (26–76) OS, PFS No surgery Mixed 15.5 ROC curve analysis
Bacha et al. [32] 2017 NSCLC France R 2010–2012 41 41 (100%) 55 (41–76) OS No surgery Metastatic 23.2 ROC curve analysis
Kobayashi et al. [33] 2018 NSCLC Japan R 2009–2014 166 74 (44.6%) OS Surgery Non-metastatic 22.2 ROC curve analysis
Tomita et al. [34] 2018 NSCLC Japan R 2008–2012 341 173 (50.7%) 69 (median) OS Surgery Non-metastatic 37.66 Cutoff Finder
Shibutani et al. [35] 2019 Colorectal cancer Japan R 2008–2016 159 87 (54.7%) 65 (18–89) OS No surgery Metastatic 28.9 ROC curve analysis
Jank et al. [36] 2019 Head and neck squamous cell carcinoma Austria R 2002–2012 93 72 (77.4%) 58 (27–72) OS, DFS Surgery Mixed 37.6 Cutoff value
  1. Abbreviations: NSCLC non-small cell lung cancer, SCLC small cell lung cancer, R retrospective, OS overall survival, PFS progression-free survival, DFS disease-free survival, Mixed included patients with metastatic and non-metastatic disease, ALI advanced lung cancer inflammation index, ROC receiver operating characteristic curve